Abstract
Currently used X-ray and laboratory methods for monitoring the effectiveness of TB treatment are not always convenient, because they give a delayed result, as in the case of sputum culture or are difficult to perform, for example, in patients with poor sputum production or patients not following instructions.
The aim of the study was to develop mathematical model for predicting the treatment effectiveness of MDR-TB based on Human-beta-defensin-1 level
Materials and methods: 50 patients with pulmonary MDR-TB were included in the study. A mathematical model was generated by discriminant functional analysis using Human-beta-defensin-1 (HBD-1) level at baseline, after 30 doses, and after 60 doses of treatment.
Results: As a result of the discriminant functional analysis, a mathematical model was obtained for predicting the MDR-TB treatment effectiveness based on the HBD-1 levels at the beginning, after 30 doses and after 60 doses of anti-TB treatment:
А = 0,1513*Def0 + 0,2661*Def30 + 0,1946Def60 - 28,4089
В = -0,01995*Def0 + 0,12139*Def30 + 0,03918*Def60 - 1,37308
where Def0 – HBD-1 at the treatment onset, Def30 – HBD-1 after 30 doses, Def60 – HBD-1 after 60 doses.
If А>В, the prognosis is unfavorable.
If А<В, the prognosis is favorable.
Conclusions: The obtained mathematical model allows predicting MDR-TB treatment effectiveness based on Human-beta-defensin-1 level.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 1278.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
